Embryonal Rhabdomyosarcoma: New Views on Rapid Recurrence & Multimodal Care

Primary peritoneal rhabdomyosarcoma (PPRMS) is an exceptionally rare and aggressive soft tissue malignancy in children. Specifically, the diagnosis of this tumor type requires a high index of suspicion. A case involving a 6-year-old girl from Ethiopia recently highlighted the severe challenges of managing this disease. She presented with lower abdominal swelling. Her initial mass was completely resected. Unfortunately, she experienced a rapid, aggressive peritoneal recurrence only five weeks after surgery. The tragic case strongly suggests the possibility of iatrogenic tumor cell peritoneal seeding during the initial procedure. Therefore, the optimal management of the highly aggressive embryonal rhabdomyosarcoma requires early, complex, and risk-adapted multimodal therapy.

Rarity and Aggressiveness of Primary Peritoneal Embryonal Rhabdomyosarcoma

Primary peritoneal rhabdomyosarcoma is an exceedingly rare form of soft tissue malignancy, making up only a small fraction of all pediatric sarcomatosis cases. Conversely, rhabdomyosarcoma typically affects the head and neck, genitourinary organs, or extremities. This specific peritoneal presentation carries a very poor prognosis. Furthermore, the tumor's aggressive nature, combined with the risk of widespread peritoneal seeding, contributes to dismal outcomes in many reported cases. The source case demonstrated this aggression clearly. The initial pathological examination confirmed embryonal rhabdomyosarcoma, a subtype more common in younger children. The rapid recurrence after an R0 (complete) resection suggests that standard surgical techniques may be insufficient to prevent microscopic spillage in this anatomical location. Therefore, surgeons must adopt preventive techniques immediately.

Surgical Strategy and Multimodal Therapy for Embryonal Rhabdomyosarcoma

The standard treatment for childhood rhabdomyosarcoma involves a multimodal approach: systemic chemotherapy, radiation therapy, and surgery. Doctors determine the optimal timing and intensity of these three components based on the patient's individual risk group assignment. Consequently, doctors generally perform surgical resection before chemotherapy only if it will not result in major disfigurement or functional compromise. If this is not possible, doctors perform only an initial biopsy. Cytoreductive surgery (CRS) followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is emerging as a potential, aggressive option for select subsets of peritoneal sarcomatosis. In fact, this approach shows promise for achieving favorable outcomes in cases without other unfavorable characteristics. Aggressive surgery alone is probably insufficient for PPRMS because of the high recurrence risk, as the current case illustrates. Multimodal therapy must start early to achieve an optimal outcome.

Frequently Asked Questions

Q1: What makes Primary Peritoneal Rhabdomyosarcoma (PPRMS) in children so aggressive?

PPRMS is an exceedingly rare and aggressive malignancy in children. Its aggressive nature, coupled with the tendency for widespread peritoneal tumor seeding, significantly contributes to the poor prognosis and rapid recurrence, as demonstrated in this case.

Q2: What is the optimal treatment for Embryonal Rhabdomyosarcoma in this location?

Optimal care requires early, risk-adapted multimodal therapy. This includes systemic chemotherapy, radiation therapy, and surgery. Experts increasingly suggest that aggressive cytoreductive surgery combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) may offer a curative intent in favorable cases, although evidence is limited.

Q3: How does surgical tumor seeding influence recurrence?

Surgical tumor seeding is a serious concern, especially with aggressive tumors like PPRMS. The case report highlights that microscopic tumor cells may spread during the initial resection (even when a complete R0 resection is achieved), leading to rapid, widespread peritoneal malignant depositions shortly after the operation. Therefore, using preventive surgical techniques is essential.

References

1. Gebreslase MN et al. Primary peritoneal embryonal rhabdomyosarcoma in a 6-year-old girl with rapid post-surgical peritoneal recurrence possibly due to surgical tumor seeding: a case report and review of the literature. J Med Case Rep. 2026 Feb 04. doi: 10.1186/s13256-026-05862-x. PMID: 41639885.


2. Kazi M, Qureshi SS. Primary Peritoneal Rhabdomyosarcomatosis in a 2-Year-Old Child Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Indian J Surg Oncol. 2021 Dec;12(Suppl 2):322-326.


3. National Cancer Institute. Childhood Rhabdomyosarcoma Treatment (PDQ®). Available from: https://www.cancer.gov/types/soft-tissue-sarcoma/patient/rhabdomyosarcoma-treatment-pdq.


4. National Cancer Institute. Childhood Rhabdomyosarcoma Treatment. Available from: https://www.cancer.gov/types/soft-tissue-sarcoma/patient/rhabdomyosarcoma-treatment-pdq.


5. Kazi M et al. Survival and Challenges with Multimodal Treatment in Children with Rhabdomyosarcoma - Real Scenario from A Resource-limited Center of Bangladesh. OncoDaily Medical Journal. 2025.